# PDE5 inhibitors for pulmonary hypertension

Drug · id `cardio:pde5-inhibitors-for-pulmonary-hypertension` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Phosphodiesterase 5 Inhibitor; Phosphodiesterase 5 Inhibitors; PDE5 inhibitors; PDE-5 inhibitors; Phosphodiesterase Type 5 Inhibitors

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

PDE5 inhibitors are medicines that block phosphodiesterase type 5, an enzyme that breaks down a signalling molecule called cGMP. The US labels of Revatio (sildenafil) and Adcirca (tadalafil) each call the product a PDE5 inhibitor indicated for the treatment of pulmonary arterial hypertension. Both labels describe the medicine as raising cGMP in the smooth muscle cells of the blood vessels of the lungs, which relaxes them. This class page covers the use for pulmonary arterial hypertension only; the same ingredients have other labels that are not covered here.

## Technical summary

Class page, scoped to the pulmonary arterial hypertension labels of the medicines. MeSH descriptor D058986 (Phosphodiesterase 5 Inhibitors, lastUpdated 2020-05-27) is a broad match: its scope note says the compounds specifically inhibit phosphodiesterase 5, and the descriptor is not limited to pulmonary hypertension. RxClass lists the established pharmacologic class on US drug labels Phosphodiesterase 5 Inhibitor for sildenafil and for tadalafil (read 2026-11-18). The labels read are Revatio (NDA203109, NDA022473, NDA021845; effective 2024-12-18) and Adcirca (NDA022332; effective 2025-12-15). Labels of the same ingredients for other uses were not read. No trial result, dose or instruction is recorded.

## Connected pages

- Files under this front: Medicines (`cardio:front-medicines`)
- The Revatio and Adcirca labels list pulmonary arterial hypertension as the indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Pulmonary arterial hypertension is one type of pulmonary hypertension: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Has subtype: Sildenafil (`cardio:sildenafil`)
- Has subtype: Tadalafil (`cardio:tadalafil`)

## Provenance

Content hash: bf8ea453ea8d5a3210c066b2733c9dafc01d75c5297568ec3a7cb38df6aaa1b4
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
